妊娠期糖尿病筛查:美国预防服务工作组更新证据报告与系统综述
本更新系统综述纳入76项研究(18项随机临床试验,n=31 241),评估妊娠期糖尿病筛查与治疗获益。直接比较筛查与不筛查的证据有限且不一致;一步法与两步法筛查对健康结局无显著改善;但治疗可显著降低剖宫产、肩难产、巨大儿等风险。
要点
- 筛查与不筛查的直接获益证据有限且不一致。
- 一步法较两步法增加GDM诊断率,但未改善健康结局。
- 治疗GDM可降低剖宫产、肩难产、巨大儿等风险。
核心结论
- 筛查与不筛查的直接证据仍有限,一步法与两步法筛查未显著改善健康结局,但治疗妊娠期糖尿病可显著改善健康结局。
研究设计与样本
- 系统综述纳入76项研究:18项随机临床试验(n=31 241)、2项非随机干预研究(n=190)、56项观察性研究(n=261 678)。
- 检索MEDLINE、EMBASE、CINAHL(2010年至2020年5月)、ClinicalTrials.gov及参考文献,监测至2021年6月。
主要发现
- 5项随机临床试验(n=25 772)中,一步法较两步法筛查显著增加妊娠期糖尿病诊断率(11.5% vs 4.9%),但未改善健康结局。
- 治疗妊娠期糖尿病(基于8项随机临床试验和1项非随机研究,n=3982)显著降低初次剖宫产(RR 0.70,95%CI 0.54-0.91;ARD 5.3%)、肩难产(RR 0.42,95%CI 0.23-0.77;ARD 1.3%)、巨大儿(RR 0.53,95%CI 0.41-0.68;ARD 8.9%)、大于胎龄儿(RR 0.56,95%CI 0.47-0.66;ARD 8.4%)及新生儿重症监护入院(RR 0.73,95%CI 0.53-0.99;ARD 2.0%)。
- 治疗与早产风险降低的关联不显著(RR 0.75,95%CI 0.56-1.01);出生损伤风险降低(OR 0.33,95%CI 0.11-0.99;ARD 0.2%)。
关键数值与推荐
- 口服葡萄糖激发试验140 mg/dL切点(针对Carpenter and Coustan标准)灵敏度82%、特异度82%;135 mg/dL切点灵敏度93%、特异度79%。
- 口服葡萄糖激发试验140 mg/dL切点(针对国家糖尿病数据组标准)灵敏度85%、特异度81%。
- 空腹血浆葡萄糖85 mg/dL切点(针对Carpenter and Coustan标准)灵敏度88%、特异度73%;90 mg/dL切点灵敏度81%、特异度82%。
临床怎么用
- 妊娠24周及以后可考虑筛查妊娠期糖尿病,筛查试验选择需权衡灵敏度与特异度。
- 确诊妊娠期糖尿病后应积极治疗,以降低剖宫产、肩难产、巨大儿等风险。
局限性
- 筛查与不筛查的直接比较证据仅来自4项观察性研究,结果不一致且存在方法学局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Gestational diabetes is associated with several poor health outcomes. OBJECTIVE: To update the 2012 review on screening for gestational diabetes to inform the US Preventive Services Task Force. DATA SOURCES: MEDLINE, EMBASE, and CINAHL (2010 to May 2020), ClinicalTrials.gov, reference lists; surveillance through June 2021. STUDY SELECTION: English-language intervention studies for screening and treatment; observational studies on screening; prospective studies on screening test accuracy. DATA EXTRACTION AND SYNTHESIS: Dual review of titles/abstracts, full-text articles, and study quality. Single-reviewer data abstraction with verification. Random-effects meta-analysis or bivariate analysis (accuracy). MAIN OUTCOMES AND MEASURES: Pregnancy, fetal/neonatal, and long-term health outcomes; harms of screening; accuracy. RESULTS: A total of 76 studies were included (18 randomized clinical trials [RCTs] [n = 31 241], 2 nonrandomized intervention studies [n = 190], 56 observational studies [n = 261 678]). Direct evidence on benefits of screening vs no screening was limited to 4 observational studies with inconsistent findings and methodological limitations. Screening was not significantly associated with serious or long-term harm. In 5 RCTs (n = 25 772), 1-step (International Association of Diabetes and Pregnancy Study Group) vs 2-step (Carpenter and Coustan) screening was significantly associated with increased likelihood of gestational diabetes (11.5% vs 4.9%) but no improved health outcomes. At or after 24 weeks of gestation, oral glucose challenge tests with 140- and 135-mg/dL cutoffs had sensitivities of 82% and 93%, respectively, and specificities of 82% and 79%, respectively, against Carpenter and Coustan criteria, and a test with a 140-mg/dL cutoff had sensitivity of 85% and specificity of 81% against the National Diabetes Group Data criteria. Fasting plasma glucose tests with cutoffs of 85 and 90 mg/dL had sensitivities of 88% and 81% and specificities of 73% and 82%, respectively, against Carpenter and Coustan criteria. Based on 8 RCTs and 1 nonrandomized study (n = 3982), treatment was significantly associated with decreased risk of primary cesarean deliveries (relative risk [RR], 0.70 [95% CI, 0.54-0.91]; absolute risk difference [ARD], 5.3%), shoulder dystocia (RR, 0.42 [95% CI, 0.23-0.77]; ARD, 1.3%), macrosomia (RR, 0.53 [95% CI, 0.41-0.68]; ARD, 8.9%), large for gestational age (RR, 0.56 [95% CI, 0.47-0.66]; ARD, 8.4%), birth injuries (odds ratio, 0.33 [95% CI, 0.11-0.99]; ARD, 0.2%), and neonatal intensive care unit admissions (RR, 0.73 [95% CI, 0.53-0.99]; ARD, 2.0%). The association with reduction in preterm deliveries was not significant (RR, 0.75 [95% CI, 0.56-1.01]). CONCLUSIONS AND RELEVANCE: Direct evidence on screening vs no screening remains limited. One- vs 2-step screening was not significantly associated with improved health outcomes. At or after 24 weeks of gestation, treatment of gestational diabetes was significantly associated with improved health outcomes.
引用
- Pillay J, Donovan L, Guitard S, et al. Screening for Gestational Diabetes: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021. PMID: 34374717. doi:10.1001/jama.2021.10404
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。